SMO Clinplus Co (SZSE:301257) Gross-Profit-to-Asset % : 13.66% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is SMO Clinplus Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. SMO Clinplus Co's annualized Gross Profit for the quarter that ended in Mar. 2024 was ¥186.9 Mil. SMO Clinplus Co's average Total Assets over the quarter that ended in Mar. 2024 was ¥1,368.9 Mil. Therefore, SMO Clinplus Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 13.66%.

SMO Clinplus Co Gross-Profit-to-Asset % Historical Data

The historical data trend for SMO Clinplus Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SMO Clinplus Co Gross-Profit-to-Asset % Chart

SMO Clinplus Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

53.17

36.86

37.66

20.45

18.29

SMO Clinplus Co Quarterly Data
	Dec17	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															13.10	19.68	20.60	19.89	13.66

Competitive Comparison of SMO Clinplus Co's Gross-Profit-to-Asset %

For the Diagnostics & Research subindustry, SMO Clinplus Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SMO Clinplus Co's Gross-Profit-to-Asset % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SMO Clinplus Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where SMO Clinplus Co's Gross-Profit-to-Asset % falls into.

SMO Clinplus Co Gross-Profit-to-Asset % Calculation

SMO Clinplus Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	231.102	/	( (1160.719	+	1366.819)	/ 2 )
	=	231.102	/	1263.769
	=	18.29 %

SMO Clinplus Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	186.948	/	( (1366.819	+	1371.069)	/ 2 )
	=	186.948	/	1368.944
	=	13.66 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

SMO Clinplus Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of SMO Clinplus Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

SMO Clinplus Co (SZSE:301257) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SMO Clinplus Co Ltd (SZSE:301257) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 105 Sinan Road, Room 108, Building 1, Huangpu District, Shanghai, CHN, 200001

Website

http://www.smo-clinplus.com

SMO Clinplus Co Ltd is engaged in providing SMO services to domestic and foreign pharmaceutical companies, medical device companies and clinical research and development of some health-related products. The services provided include Preliminary model establishment, Preliminary plan preparation, Initiation of clinical trial sites, On-site implementation, and Comprehensive project management.

Executives

Lai Chun Bao	Director
Ma Lin	Director

SMO Clinplus Co (SZSE:301257) Headlines

No Headlines